Business

Alvotech Reports Record-Breaking First Half of 2025 Amid Strong Biosimilar Sales

August 27th 2025

By Skylar Jeremias

Alvotech achieves a remarkable financial turnaround in 2025, reporting a net profit driven by strong biosimilar sales and strategic partnerships.

Ten Years of Data Support Safety of Biosimilar Filgrastim for Donor Mobilization

August 22nd 2025

By Skylar Jeremias

Article

A 10-year prospective follow-up of 244 healthy stem cell donors found no new safety concerns with Sandoz’s filgrastim biosimilar, reinforcing its long-term safety for donor mobilization.

Litigation, Launch, and Lower Costs: 3 Big Moves in the US Biosimilar Space

August 19th 2025

By Skylar Jeremias

Article

Explore groundbreaking developments in biosimilars, including patent lawsuits, new ustekinumab launches, and innovative access strategies for patients.

Low Prices Fail to Boost Insulin Biosimilar Uptake in the UK

August 11th 2025

By Skylar Jeremias

Article

Biosimilar insulin glargine struggles for market share in the UK, facing pricing challenges and prescriber inertia despite regulatory support and cost-saving potential.

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

July 27th 2025

By Skylar Jeremias

Podcast

Explore the evolving biosimilars landscape with expert insights on development, regulation, and global health harmonization in this engaging podcast episode.

Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap

July 16th 2025

By Skylar Jeremias

Article

Government price negotiations under the Inflation Reduction Act may hinder biosimilar development, impacting drug costs and patient access to affordable therapies.

White Paper Offers Tips for Sustaining Biosimilar Progress, Avoiding a Market Void

July 15th 2025

By Skylar Jeremias

Article

Biosimilars face a potential void as biologics lose exclusivity, prompting urgent calls for policy reform and enhanced education to ensure market sustainability.

Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan

June 17th 2025

By Skylar Jeremias

Article

Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.

Sandoz, STADA, and Samsung Bioepis Report Strong Earnings From Biosimilars

June 10th 2025

By Skylar Jeremias

Article

Leading biosimilar companies Sandoz, STADA Arzneimittel, and Samsung Bioepis report impressive Q1 2025 growth, driven by strong denosumab biosimilars and expanding portfolios.

Billions in Health Care Savings Realized Through Early Generic, Biosimilar Settlements

June 4th 2025

By Skylar Jeremias

Article

Patent settlements accelerate the entry of generics and biosimilars, saving the health care system $422.9 billion and enhancing drug accessibility.